FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3172002536> ?p ?o ?g. }

• W3172002536 endingPage "5527" @default.
• W3172002536 startingPage "5527" @default.
• W3172002536 abstract "5527 Background: Treatment options for patients with recurrent cervical and endometrial cancer remain limited. Even with optimum care, median survival has stalled at 12-17 months. The PARP inhibitor rucaparib has demonstrated activity in both BRCA wild-type and mutant cancers. Furthermore, preclinical studies suggest a synergistic effect of PARP inhibitors and antiangiogenic agents. We hypothesized that the combination of rucaparib and the VEGF inhibitor bevacizumab would yield a clinically-significant anti-cancer effect in patients with persistent or recurrent cervical or endometrial carcinoma. Methods: NCT03476798 is a phase II trial of adults with histologically-documented carcinoma of the cervix or endometrium. Patients with evaluable lesions who had undergone at least one prior line of systemic therapy, had adequate performance status and organ function, with a life expectancy of at least three months were eligible. Biopsies were obtained prior to treatment initiation for assessment of baseline tumor biomarkers, including ARID1A mutation status. Each cycle comprised 21 days. Rucaparib was administered orally at 600 mg, twice daily. Bevacizumab was administered by IV at 15 mg/kg on day 1 of each cycle. The primary objective was to estimate the proportion of patients with persistent or recurrent cervical or endometrial cancer who survive progression-free for at least six months (PFS6). Kaplan-Meier analysis was used to estimate progression-free survival. Results: There were 28 evaluable patients; six had cervical and 22 had endometrial cancer. Median age was 60.5 years (range, 30-74). Self-reported patient races were White (82.1%), Black (10.7%), and Native American (7.1%). Self-identified Hispanic or Latina patients comprised 3.6% of the cohort. Twenty-two of 28 patients had progressive disease by six months [survival distribution function estimate = 0.214 (lower CI, 0.087; upper CI, 0.378)]. Of the six patients who achieved PFS6, one had cervical and five had endometrial cancer. Six patients had a mutation in the ARID1A gene and those patients achieved PFS6 at a rate of 66.7%. Conclusions: The study hypothesis was evaluated in a two-stage design, and the interim analysis occurred once 28 evaluable patients were enrolled. In order to move on to the second stage, at least seven patients needed to remain progression-free at six months, but only six did. Thus, the study was ended after the interim analysis. The combination of rucaparib and bevacizumab did not provide the expected clinical benefit in this cohort of patients, but may warrant further exploration in patients with ARID1A mutations. Clinical trial information: NCT03476798." @default.
• W3172002536 created "2021-06-22" @default.
• W3172002536 creator A5002992087 @default.
• W3172002536 creator A5004006667 @default.
• W3172002536 creator A5009967316 @default.
• W3172002536 creator A5012909246 @default.
• W3172002536 creator A5018998777 @default.
• W3172002536 creator A5020389827 @default.
• W3172002536 creator A5037201634 @default.
• W3172002536 creator A5047437197 @default.
• W3172002536 creator A5053990407 @default.
• W3172002536 creator A5054372225 @default.
• W3172002536 creator A5057447088 @default.
• W3172002536 creator A5061736280 @default.
• W3172002536 creator A5069337573 @default.
• W3172002536 creator A5069435273 @default.
• W3172002536 creator A5077115315 @default.
• W3172002536 creator A5091030588 @default.
• W3172002536 date "2021-05-20" @default.
• W3172002536 modified "2023-10-14" @default.
• W3172002536 title "A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium." @default.
• W3172002536 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.5527" @default.
• W3172002536 hasPublicationYear "2021" @default.
• W3172002536 type Work @default.
• W3172002536 sameAs 3172002536 @default.
• W3172002536 citedByCount "0" @default.
• W3172002536 crossrefType "journal-article" @default.
• W3172002536 hasAuthorship W3172002536A5002992087 @default.
• W3172002536 hasAuthorship W3172002536A5004006667 @default.
• W3172002536 hasAuthorship W3172002536A5009967316 @default.
• W3172002536 hasAuthorship W3172002536A5012909246 @default.
• W3172002536 hasAuthorship W3172002536A5018998777 @default.
• W3172002536 hasAuthorship W3172002536A5020389827 @default.
• W3172002536 hasAuthorship W3172002536A5037201634 @default.
• W3172002536 hasAuthorship W3172002536A5047437197 @default.
• W3172002536 hasAuthorship W3172002536A5053990407 @default.
• W3172002536 hasAuthorship W3172002536A5054372225 @default.
• W3172002536 hasAuthorship W3172002536A5057447088 @default.
• W3172002536 hasAuthorship W3172002536A5061736280 @default.
• W3172002536 hasAuthorship W3172002536A5069337573 @default.
• W3172002536 hasAuthorship W3172002536A5069435273 @default.
• W3172002536 hasAuthorship W3172002536A5077115315 @default.
• W3172002536 hasAuthorship W3172002536A5091030588 @default.
• W3172002536 hasConcept C104317684 @default.
• W3172002536 hasConcept C121608353 @default.
• W3172002536 hasConcept C126322002 @default.
• W3172002536 hasConcept C143998085 @default.
• W3172002536 hasConcept C182979987 @default.
• W3172002536 hasConcept C185592680 @default.
• W3172002536 hasConcept C2776694085 @default.
• W3172002536 hasConcept C2777088508 @default.
• W3172002536 hasConcept C2777546739 @default.
• W3172002536 hasConcept C2777740455 @default.
• W3172002536 hasConcept C2777802072 @default.
• W3172002536 hasConcept C2778220009 @default.
• W3172002536 hasConcept C2779138821 @default.
• W3172002536 hasConcept C55493867 @default.
• W3172002536 hasConcept C71924100 @default.
• W3172002536 hasConcept C82381507 @default.
• W3172002536 hasConceptScore W3172002536C104317684 @default.
• W3172002536 hasConceptScore W3172002536C121608353 @default.
• W3172002536 hasConceptScore W3172002536C126322002 @default.
• W3172002536 hasConceptScore W3172002536C143998085 @default.
• W3172002536 hasConceptScore W3172002536C182979987 @default.
• W3172002536 hasConceptScore W3172002536C185592680 @default.
• W3172002536 hasConceptScore W3172002536C2776694085 @default.
• W3172002536 hasConceptScore W3172002536C2777088508 @default.
• W3172002536 hasConceptScore W3172002536C2777546739 @default.
• W3172002536 hasConceptScore W3172002536C2777740455 @default.
• W3172002536 hasConceptScore W3172002536C2777802072 @default.
• W3172002536 hasConceptScore W3172002536C2778220009 @default.
• W3172002536 hasConceptScore W3172002536C2779138821 @default.
• W3172002536 hasConceptScore W3172002536C55493867 @default.
• W3172002536 hasConceptScore W3172002536C71924100 @default.
• W3172002536 hasConceptScore W3172002536C82381507 @default.
• W3172002536 hasFunder F4320315087 @default.
• W3172002536 hasIssue "15_suppl" @default.
• W3172002536 hasLocation W31720025361 @default.
• W3172002536 hasOpenAccess W3172002536 @default.
• W3172002536 hasPrimaryLocation W31720025361 @default.
• W3172002536 hasRelatedWork W1970772780 @default.
• W3172002536 hasRelatedWork W2075148081 @default.
• W3172002536 hasRelatedWork W2328502883 @default.
• W3172002536 hasRelatedWork W2514884906 @default.
• W3172002536 hasRelatedWork W2590783779 @default.
• W3172002536 hasRelatedWork W2953526414 @default.
• W3172002536 hasRelatedWork W3128010851 @default.
• W3172002536 hasRelatedWork W4214497009 @default.
• W3172002536 hasRelatedWork W4239855218 @default.
• W3172002536 hasRelatedWork W4362400444 @default.
• W3172002536 hasVolume "39" @default.
• W3172002536 isParatext "false" @default.
• W3172002536 isRetracted "false" @default.
• W3172002536 magId "3172002536" @default.
• W3172002536 workType "article" @default.